Clinical Trial Detail

NCT ID NCT02068079
Title A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Duke University
Indications

melanoma

Therapies

Trientine + Vemurafenib

Age Groups: senior adult

Additional content available in CKB BOOST